Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.
Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.
advertisement
This is a familiar but tiring refrain.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
PhRMA lawsuit over Medicare drug price negotiation tossed
Next article： Heart attack and stroke risk calculators need revising
Next article： Heart attack and stroke risk calculators need revising
